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ABSTRACT 
 
 
 
AlAli Sally M.S. Department of Microbiology and Immunology, Wright State University,  
2013. TLED Novel Approaches For The Eradication Of HIV Latently Infected Cells. 
 
 
The development of a suitable experimental cell model to study HIV latency in primary 
cells could have a massive effect on the current approaches to eradicate virus in latently 
infected cells. The main proposal of this paper is to develop an in vitro HIV cell model 
that represents HIV latency in vivo, then to create a more effective viral vector in order to 
target HIV reservoirs.   For this goal, a directed evolution method is suggested to be used 
in order to mutate the AAV cap gene to generate a recombinant AAV vector that is 
capable of infecting primary resting CD4+ T cells previously infected with HIV-1 and in 
a latent stage. 
 
 
 
 
 
 
 
 
iv 
 
 
Table of Contents 
 
 
INTRODUCTION………………………………………………………….1 
BACKGROUND……………………………………………………………5 
AN OVERVIEW OF THE METHOD………………………………………18 
REFERENCES……………………………………………………………….22 
 
 
 
 
 
 
 
 
 1 
 
 
I. INTRODUCTION 
Human immunodeficiency virus (HIV) is a lentivirus in the Retroviridae family. 
HIV causes acquired immunodeficiency syndrome (AIDS) in humans. Although the 
development of highly active antiretroviral therapy (HAART) has increased life 
expectancy, HIV reservoirs are still an obstacle to the eradication of the virus.  
HIV latency is a big challenge scientists face to completely eliminate HIV from 
patients’ bodies. In order to eradicate HIV latently infected cells, there is a big need to 
understand the mechanism of HIV latency. One strategy is to prevent latency. Another 
strategy for complete HIV eradication is to identify biomarkers for latently infected cells, 
in order to target them in vivo. Targeting HIV reservoirs can be done either by anti-
retrovirus drugs, or gene therapy. Anti-retrovirus drugs could be a possible way for full 
HIV eradication if it is specifically designed for eliminating HIV reservoirs. Gene 
therapy is another targeting strategy; it is a promising approach for targeting latent 
reservoirs.  
The main challenge in understanding HIV latency is to have a paradigm that is 
similar to in vivo latency. Studying HIV latency in vitro is an obstacle due to the lack of a 
cell model that represents HIV latent reservoirs.  The lack of cell model representing HIV 
latency is behind the reason that latency establishment is possible to start in multiple 
mechanisms. . A cell model representing HIV latency would allow the investigation of 
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these mechanisms. Moreover, HIV reservoirs are likely to be persistent in several cell 
types (Bosque and Planelles, 2011).   
 Numerous efforts have been undertaken to create a novel cell model to study HIV 
latency. Some of the early efforts to study latency have investigated chronically infected 
cell lines such as JΔK (Antoni et al., 1994) and ACH2 (Jordan  et al., 2003). JΔK cells 
originated from the Jurkat T cell line. These cells are infected with HIV-1 virus, which 
has deletion on its long terminal repeat (LTR) at the NFκB binding site. (Antoni et 
al.,1994) these cells are different from primary cells because it is proliferating constantly. 
Therefore, these cells never enter a quiescent stage. In the ACH2 cell model, tumor 
necrosis factor – alpha (TNF-α) can reactivate the HIV latent virus  (Jordan  et al., 2003). 
However, Tyagi, et al. (2010) reported no latent HIV-1 reactivation by TNF-α in a 
primary CD4+ latently infected cell model.  
Brooks, et al. (2001) generated an animal model by implanting a human fetal 
thymus and liver tissues into severe-combined immunodeficient mice (Thy/Liv SCID-
hu). This animal model is likely to be a promising alternative to in vitro research. The 
model created by Brooks and colleagues allows the study of latency in naïve CD4+ T 
cells, which contributes to 1.9% of HIV-1 reservoirs, while T central memory cells (TcM) 
contribute with 51.7% and T transitional memory (TTM) gives about 34.3% (Chomont  et 
al., 2010).  
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There have been several models developed that utilize primary T cells in order to 
study latency. Primary T cells are permitted to enter latency after activation and infection 
with HIV vectors. Several strategies have been used for this purpose such as, incubating   
latently infected T cells with IL-7 (Marini et al. 2008), or taking advantage of CD4+ T 
cells which can have an intermediate level of differentiation between two T cell subsets, 
naïve T cells and effector T cells (Bosque and Planelles, 2011). This intermediate or un 
committed phenotype will be referred to as non polarized CD4+ T cells in this paper. 
Studies of HIV latency in previous cell models have given us deeper knowledge 
about the possible mechanisms of latency. Understanding the mechanism of latency could 
provide insights into promising approaches to prevent latency. However, there is a greater 
possibility that latency may not be preventable from occurring. Therefore, targeting HIV-
1 reservoirs may be a more efficient way to achieve full eradication of HIV from the 
body. 
Identifying biomarkers for HIV reservoirs is an important step to target latently 
infected cells. Several studies have reported that the majority of HIV reservoirs are TcM 
and TTM subsets (Chomont et al., 2010), which both share the expression of CD45RO
+  
(Bosque and Planelles, 2011). Tyagi et al. (2010) identified HIV reservoirs, in the novel 
HIV latently infected cell model created by his team, as CD45RA
-
, CD45RO
+,
 CD27
low
, 
CCR7
low
, CD25
-
, and CD38
+
. This finding is consistent with previous studies, which 
suggest that TcM subsets represent HIV latently infected cells (Okada et al., 2008).  
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 Several previous studies have used HIV-based vectors or replication deficient 
HIV virus to infect CD4+ cells. In this paper, I propose to use wild type HIV to infect 
primary restingCD4+ T cells in order to determine whether the latently infected cells will 
express the same biomarkers reported in previous studies.  The second objective in this 
study will be to infect the HIV latently infected cells with an adeno-associated virus 
(AAV), which will be created using a directed evolution technique, in order to originate a 
novel therapeutic approach using gene therapy. This approach would be a more 
promising and convenient method if combined with HAART regimen for full HIV 
eradication. 
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II.  BACKGROUND 
  The development of the high active antiretroviral therapy (HAART) has a huge 
impact on controlling HIV infection, by acting on different phases of HIV life cycles. 
This treatment has improved HIV patients’ life expectancy, by maintaining immune 
system functions. It also protects patients from the opportunistic infections that frequently 
cause death cases among acquired immunodeficiency syndrome (AIDS) patients.  
Despite HAART improving the quality of life in HIV patients; therapy approaches have 
not been able to eradicate HIV reservoirs. These reservoirs can persist in patient’s body 
for approximately 44 months; these resting memory CD4+ T cells have low decay rates. 
Thus, it takes about 60 years for full HIV eradication (Siciliano  et al,. 2003). 
 HIV latently infected cells or HIV reservoirs are established early, during HIV 
acute infection after initial infection. It is believed that memory T cells are the main 
reservoir for HIV (Chomont  et al., 2010). Moreover, Chomont  et al. (2010) reported 
TcM isolated from HIV-1 aviremic patients forms the majority of HIV-1 latently infected 
cells. The same team also reported the presence of TTM subsets in the pool of HIV-1 
reservoirs (Chomont  et al.,  2010). 
 HIV latently infected cells are in resting stage in vivo. Resting stage is identified 
by the lack of cell activation markers, such as CD25, CD69, and HLADR (Bacchus et al., 
2013). HIV reservoirs are found in G0, which means decreased levels of cellular DNA 
and RNA synthesis (Richman., 1980). The necessity of cells entering G0 to become HIV 
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latent cells has not been investigated.  Another question with no answer is whether 
transition from G0 to G1 phase is a crucial step for HIV reactivation. 
There are three possible mechanisms for HIV latency in vivo. The first 
mechanism suggests the return of an activated CD4+ T cell to the resting state after the 
integration of HIV provirus. But for an activated, infected CD4+ T cell to survive, it must 
escape activation-induced cell death because it eradicates the majority of activated cells. 
Moreover, the cell must survive the HIV cytopathic effect (Shen  et al., 2000). 
Another possible theory for the establishment of HIV latency is that T cells allow 
reverse transcription and integration. However, this reverse transcription is not sufficient 
for viral replication. Infection through this time will allow the cell to avoid the HIV 
cytopathic effect (Shen  et al., 2000). 
A third suggested mechanism for the establishment of HIV latency reported the 
ability of resting CD4+ T cells to allow HIV integration and gene expression when these 
cells are treated with cytokines such as IL-2, IL-7, IL-15  (Unutmaz  et al., 1999).  
These three hypotheses have not been investigated due to the difficulty in creating 
an HIV latently infected cell model. It is hard to create a cell model that represents all cell 
types that associate with HIV latency in vitro because multiple cell types are involved in 
HIV latency in vivo. A second reason for the difficulty is that we still don’t know which 
cytokine mechanism or pathway is significant in HIV reactivation in vivo (Yang et al. 
2009). Last two decades have provided several studies aimed focused on understanding 
the latency mechanism. Some of these studies investigate latency in chronically HIV-
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infected cell lines (Antoni et al., 1993; Jordan  et al., 2003), animal models (Brooks et al., 
2001), And primary cell culture (Tyagi et al,. 2010; Bosque and Planelles, 2011; Saleh et 
al., 2010). 
Jordan  et al. (2003) created a latent HIV cell model using the ACH2 cell line. 
This model is based on chronically infected T cells generated from the parental T cell 
line, A3.01, that includes latent pro virus (Jordan et al., 2003). In this cell line Jordan and 
colleagues reported that reactivation of HIV-1 from latency could occur after adding 
TNF-α to the medium. However, the ACH2 cell line cannot represent true HIV latency 
because this finding is different than Tyagi et al. who found no evidence of HIV-1 
reactivation in HIV-1 latently infected cells in a primary isolated T cells upon TNF-α 
treatment (Tyagi  et al., 2010). 
 Another cell model based on a chronically infected cell line is the JΔK cell 
model. In this model, cells are derived from the Jurkat cell line and chronically infected 
with an HIV serotype that has a deletion in the long terminal repeat (LTR) at the NFκB 
binding site (Antoni et al., 1993). In this model HIV-1 reactivation occurs in a fashion 
independent of NFκB by incubating cells with PMA, hexamethylene bisacetamide or 
sodium butyrate (Antoni, et al., 1993). More investigation is needed to know the effect of 
the previous materials on any cell model that represents HIV latency in a more similar 
way.  
Antoni and Tyagi cell models gave us a deeper knowledge of a group of cytokines 
that are associated with HIV-1 reactivation. However, the previous cell models are not 
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completely parallel to the resting CD4+ T cells in G0 phase in HIV infected individuals 
(Chun et al., 1997; Finzi  et al., 1999) 
Another different approach to create an HIV latently infected cell model was 
originally created by Brooks et al. (2001). Using an animal model, Brooks and coworkers 
developed an animal model using severe-combined immunodeficient mice that have an 
implanted human fetal thymus (Brooks et al., 2001). Brooks and colleges generated 
latency at a high rate during thymopoiesis. The vast majority of latent cells in this in vivo 
model are naïve CD4+ T cells (Brooks et al., 2001). Naïve CD4+ T cells represents 1.9 
% of HIV latently infected cells while TcM and TTM represent 51.7 and 34.3% 
respectively (Chomont et al., 2009; OstrowskI. et al., 1999). Therefore, using this animal 
cell model is promising for studying HIV latency in naïve CD4+ T cells. However, naïve 
CD4+ T cells represent the minority in the population of HIV reservoirs.  
Another possible strategy to create HIV latency cell model is the ex vivo culturing 
of peripheral blood mononuclear cells (PBMC). By growing CD4+ T cells ex vivo, we are 
generating a more parallel paradigm to HIV latency in vivo.  There are two main 
challenges in using primary cells to create an ex vivo cell model for HIV latency. The 
first challenge is the short half-life of the primary cells. These cells cannot survive more 
than 20 days in vitro (Saleh et al., 2007; Peace et al., 2012). The second challenge is the 
limited cell numbers obtained from these models (Peace et al., 2012; Bosque et al., 
2009). Several trials were established to obtain a cell model that represents HIV 
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reservoirs in vivo using different strategies such as, non-polarized T cells (Bosque et al., 
2009), Bcl-2 cDNA transduced CD4+ T cells (Yang et al., 2009), and activated T cells 
co-cultured with a feeder cell line (Tyagi et al., 2010). 
Bosque and coworkers (2009) took advantage of non-polarized cells since they 
can be activated to Th1 and Th2 T cells or stay inactivated as TcM. The cells were 
infected with an env deficient HIV (DHIV), then cultured with medium that included IL-
2 (Bosque et al,. 2009). Although this cell model generated a large number of latently 
infected cells with different subtypes, cell viability was 20% at the end of the resting 
stage (Bosque et al., 2009). An important advantage of this model is the convenience of 
drug screening that could target various steps of HIV latency. However, this model is not 
perfect for studying HIV that targets chemokine receptor (R5 tropic virus) since these 
cells express lower CCR5 levels due to the activation step.  
Yang et al. (2009) transduced primary cells with lentiviral vector that expressed 
the B cell lymphoma-2 gene (BCL-2), which encodes an anti-apoptotic protein located 
downstream of IL-7 signaling (Yang, et al., 2009). Therefore, Inhibition of apoptosis 
allowed cells to survive longer independent of cytokine stimulation. This model 
generated enough cells, which is optimal for drug screening. However, the majority of 
model cells developed by Yang et al. (2009) generated effector memory T cells. These 
cells are the second minority after naïve T cells in HIV reservoirs pool (Chomont, et al. 
2009). Moreover, mutated HIV vector could potentially affect the results because it does 
not represent HIV wild type accurately.  
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Tyagi and colleagues (2010) infected activated primary CD4+ T cells isolated 
from healthy donors. After activation and infection with mutated HIV vector, cells were 
co-cultured with an H80 feeder cell line (Sahu  et al,. 2006; Tyagi  et al.,  2010). This cell 
model overcame the problem of the short half-life of latent cell models ex vivo (Sahu et 
al., 2006; Tyagi et al., 2010). Also, this cell model showed that epigenetic silencing and 
restricted P-TEFb levels contribute to HIV latency (Tyagi, et al., 2010). However, co-
culturing activated CD4+ T cells with the H80 feeder cell line results in a comparatively 
homogenous population of TcM (Tyagi et al., 2010). This means that the Tyagi and 
colleagues (2010) cell model does not allow the study of other T cell subsets that 
contribute to HIV latent cells pool such as the TTM subset (Chomont, et al., 2009). 
Furthermore, cells in nature are not completely resting as it appears in Tyagi and 
coworkers’ cell model, CD25
high
 and Ki67
high
 which means that these cells are actively 
proliferating (Tyagi et al., 2010). Finally, the use of mutated HIV may affect the behavior 
of the latent virus. 
The latent cell models discussed previously used activated T cells (Bosque et al., 
2009; Yang et al., 2009; Sahu et al., 2006: Tyagi et al., 2010), using activated T cells in 
HIV latent cell models can produce a large number of cells, which is suitable for drug 
screening (Bosque et al., 2009; Yang et al., 2009). However, activated T cells in a latent 
model result in a homogenous population of one T cell subset, such as a TcM population, 
resulted after activated T cells were co-cultured for a long period of time with H80 feeder 
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cells (Sahu et al., 2006; Tyagi et al., 2010). Thus, using activated T cells, as an HIV 
latent cell model does not parallel HIV latency in vivo. There is a big need to study HIV 
latency in a cell model that represents HIV reservoirs in vivo. The more similar the model 
is to in vivo HIV latency the greater benefit we get in identifying reservoirs and the 
biomarkers on these cells. Identifying biomarkers of HIV reservoirs is a promising 
strategy in targeting these cells to full HIV eradication.  
 The using of resting T cells in creating an HIV latent cell model could represent 
in vivo HIV latency in a more precise way. Direct infection of primary resting CD4+ T 
cells prevents any stimulation or activation that could change cellular characteristics, thus 
we can obtain CD4+ T cells potentially as they exist in the body. It is predicted that using 
resting cells will give us more accurate results, and it will allow us to study latency in all 
T cell types. Peace and colleagues (2012) developed an HIV latent cell model using 
resting T cells. In this cell model resting cells were spinoculated with HIV WT to 
increase infection. This experiment was done to measure the integration, transcription, 
and translation of HIV proteins; it shows that resting CD4+ cells have the ability to 
produce HIV Gag protein without enhancing the spread of infection (Peace et al., 2012). 
This study reflects the latency features of HIV in vivo. Also, it can give us more accurate 
results for T cells biomarkers as they are in the body. However, T cells in the Peace and 
coworkers cell model do not survive for longer than 20 days in vitro (Peace et al., 2012).  
This is considered a disadvantage in studying HIV latent cells, particularly when studying 
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HIV latency for drug screening or gene therapy.  
Identifying biomarkers for HIV reservoirs is necessary to develop strategies to 
target these cells efficiently. Several studies identified biomarkers for HIV latent cells in 
primary CD4+ T cell (Tyagi et al., 2010; Bosque et al., 2009). These two studies revealed 
similar features of latently infected CD4+ T cells, which are CD45RA
-
, CD45RO
+
, 
CCR7
+
, CD27
+
. These cell markers show that HIV latent cells have the central memory 
T cells phenotype (Tyagi et al., 2010; Bosque et al., 2009). Additionally, Tyagi and 
colleagues investigated the cell proliferative state by detecting the nuclear proliferation 
markers Ki67 and BrdU in HIV latently infected cells in the cell model (Tyagi et al., 
2010). The results show that the majority but not all latent cells are quiescent. Tyagi and 
coworkers suggest that the Ki67 positive cells are viable for a longer time when treated 
with IL-2  (Tyagi et al., 2010). However, both Tyagi and Bosque previous studies were 
done in cell models that were not quite parallel to in vivo HIV latency since Tyagi’s 
model resulted in a homogenous T cells subset of T central memory cells (Tyagi et al., 
2010), and the Bosque cell model had a majority of non-polar T cells that express 
CD45RA
+ 
(Bosque et al., 2009). On the other hand, Bacchus and colleagues identified 
biomarkers for HIV reservoir in vivo, which were CD25
-
, CD69
-
, and HLADR
-
 (Bacchus 
et al. 2013). Additionally, this study revealed four resting CD4+ T cells subsets that 
contribute to the different percentages of subsets found in the in vivo HIV latency pool. 
These four resting CD4+ T cells subsets are: naive (CD45RA+CCR7+CD27+) 2%, 
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central-memory (CD45RA-CCR7+CD27+) 17%, transitional memory (CD45RA-CCR7-
CD27+) 58%, and effector memory cells (CD45RA-CCR7-CD27-) 9.7% (Bacchus et al., 
2013). Comparing HIV latent cells isolated as described in the method section below to 
these studies described above using the same biomarkers will allow us to compare the 
similarity of our cell model to the in vivo HIV latent cell populations. 
Pace et al. (2012) developed a cell model that revealed an important feature of 
HIV reservoirs, which is the Gag protein persistence in these cells. Resting T cells 
produce a smaller quantity of HIV proteins and fewer types of HIV proteins (Pace et al., 
2012). Results found by Pace and coworkers are consistent with the in vivo results that 
the Gag protein is more predominant in resting cells than env and vif proteins (Zhang et 
al., 1999). Thus, targeting HIV reservoirs producing Gag protein will be more beneficial 
than targeting latent HIV cells expressing env (Berger, and Pastan, 2010)  
In this paper I propose to use primary resting CD4+ T cells without activation, 
then to infect these cells with HIV WT in order to have the advantage of a parallel cell 
model to HIV latency in vivo. Thus, identifying cell markers before and after infection 
will be more efficient to determine the changing that occurs in T cells subsets and 
phenotypes before and after infection. Another purpose of this system is to target HIV 
latent cells with adeno-associated virus (AAV). Targeting cells needs HIV latent cells to 
survive for long period. Thus, cells will be co-cultured with H80 feeder cell line to ensure 
cell survival in our cell model.  
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Gene therapy is a potential method to cure several diseases. It has shown 
encouraging results in treating diseases such as cystic fibrosis (Wagner JA, et al. 
1998; Excoffon et al., 2009), improvement of vision in Leber congenital amaurosis 
patients (Maguire et al. 2008), and severe combined immunodeficiency SCID-X1 
disease (Cavazzana et al., 2000). With using gene therapy, scientists can deliver a 
gene in order to correct a defective gene in patient’s body, or to improve cell 
capability to fight infectious agents. Thus, it can be said that gene therapy is a 
developed form of drug delivery, and it could be applied for a vaccination strategy. 
AAV is a member of of the Parvoviridae family and is a Dependovirus. 
The AAV wild type genome is 4.7 Kb, it is a linear, single stranded DNA virus 
with 2 open reading frames ORFs. The first open reading frame is rep, this area 
encodes transcripts for 4 proteins that are required for AAV genome replication. 
The second ORF is cap and encodes 3 proteins (VP1-3) that build the AAV 
capsid (Muzyczka , Berns , 2001). AAV is a potential viral vector candidate that 
may target HIV reservoirs for several reasons; first, AAV capsid is highly 
evolved; this capsid could be engineered in a way that it can change AAV tropism 
since it is encoded by a single gene (Summerford , Samulski  ,1998; Walters , et 
al., 2001; Gao et al. 2004). Mutating the AAV cap is a possible strategy to target 
cells other than those that AAV WT usually infects. The second reason that makes 
AAV a better viral vector is the high level of safety when using this virus in 
 
 15 
humans. AAV has never been documented to cause human disease (Moss et al., 
2007). Also, the ability of AAV Type 2 to infect lymphocytes was investigated in 
3 B cell subsets and 4 T cell types; the results show that AAV is able to infect all 
tested lymphocyte subsets (Mendelson et al., 1992). Moreover, AAV has been 
reported to successfully infect alveolar cells, which are mature, non-dividing cells 
(Mendelson et al., 1992). Finally, the development of synthetic biology 
techniques such as, directed evolution would be promising if it is used with AAV 
to create a mutated cap gene, which can change AAV tropism and target more cell 
types in a more efficient and specific fashion. 
Inouye and coworkers reported a strong inhibition of HIV-1 in primary T 
cells and alveolar macrophages when they delivered combined anti-Rev single-
chain immunoglobulin (SFv) or Rev response element (RRE) decoy genes 
delivered by AAV vector (Inouye, et al.,1997). It is also a promising strategy to 
create a vaccine that prevents HIV infection. Furthermore, it shows that immune 
cells (T cells and alveolar macrophages) are capable of being infected with more 
than one virus, AAV and Ad5 and HIV (Inouye, et al., 1997). However, the 
efficient delivery of this strategy has not been yet investigated.  
Mendelson et al.(1992) reported an increase of about 60-70% in HIV-1 
reverse transcription when lymphocytes are co-infected with either adenovirus or 
adeno-associated virus alone (Mendelson et al., 1992). The increase of reverse 
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transcription activity was decreased by about 20% when cells were infected with 
AAV plus Ad2 virus together (Mendelson et al., 1992). The study highlights an 
important advantage of AAV, which is the ability of these viruses to interact with 
HIV-1 after infecting lymphocytes. Thus, T cells can survive after being infected 
with 3 viruses (Mendelson et al., 1992). However, the yield of infectious AAV 
was low in most cases (Mendelson et al., 1992). The low rate of infectious AAV 
could be due to the low viral tropism to lymphocytes. Therefore, developing AAV 
cap gene for better infection of lymphocytes using directed evolution would be a 
possible way to target HIV reservoirs in our HIV latent cell model.  
The directed evolution strategy has a potential effect in changing the 
functional properties of enzymes, proteins, and genes. Directed evolution occurs 
when we applied selective pressure to a library of objects in order to get the most 
desired properties of these objects.  
Excoffon et al. (2009) demonstrated the capability of AAV to develop 
remarkably greater infectivity within the airway epithelium when a library of 
AAV cap mutants were placed under selective pressure. When the AAV vector 
was customized with the mutated AAV cap gene after directed evolution, it was 
better able to infect human airway epithelia (Excoffon  et al., 2009). Thus, using 
directed evolution to mutate AAV cap gene in order to infect HIV latent cells is 
likely a promising approach in targeting HIV reservoirs. 
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The first goal in this paper is to generate an efficient HIV latency model 
that is parallel to the in vivo HIV latency pool. Our HIV latent cell model will 
allow us to identify HIV latent cells’ biomarkers before and after being infected 
with HIV WT. To guarantee that cells will survive for longer time, cells will be 
co-cultured with the H80 feeder cell line (Sahu et al., 2006; Tyagi et al., 2010). 
Additionally, our novel cell model will give us the chance to investigate the 
reasons behind the predominant levels of HIV Gag protein in latently infected 
cells reported by Pace and colleagues (Pace et al.,  2012). The second goal of this 
study is to engineer a viral vector that is capable of infecting HIV reservoirs and 
express a GFP gene or an anti-HIV gene within these latent cells. AAV is a 
potential candidate for targeting HIV reservoirs due to its high safety profile in 
humans. Targeting HIV latent cells with AAV vector that is capable to get high 
gene expression could be a significant step towards the eradication of HIV 
reservoirs in patients’ body.  
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III. AN OVERVIEW OF THE METHOD 
T cell isolation:  
T cells will be isolated from PBMC. To purify resting T cells, we can stain 
the cells with R-Phycoerythrin (PE) Conjugated Antibodies against CD25, CD69, 
and HLA-DR, and then use Anti-PE magnetic beads (Pace et al., 2012). Pace and 
colleagues method in isolating resting CD4+ T cells has a purity greater than 98% 
(Pace et al., 2012).  
Purified cells can go through more investigation to identify resting CD4+ 
T cells biomarkers, and compare the obtained subtypes with the in vivo studies by 
Bacchus et al. (2013) The four resting CD4+ T cells subsets in this study are: 
naive (CD45RA+CCR7+CD27+) 2%, central-memory (CD45RA-CCR7+CD27+) 
17%, transitional memory (CD45RA-CCR7-CD27+) 58%, and effector memory 
cells (CD45RA-CCR7-CD27-) 9.7% (Bacchus et al., 2013) 
Incubating resting CD4+ T cells: 
Resting CD4+ T cells will left in RPMI medium, containing 10% fetal calf 
serum (FCS) and antibiotics, with no stimulation (Pace et al., 2012). 
Other resting CD4+ T cell groups will be stimulated with either IL-7 or 
anti-CD28/CD3. Stimulated CD4+ T cells will used to evaluate the differences 
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between cell markers in resting CD4+ T cell with/without stimulation, and then 
compare our results with the in vivo results by Bacchus et al. (2013). 
Stimulated and non-stimulated resting CD4+ groups will be tested for the 
following biomarkers: CD45RA, CD45RO, CCR7, CD27, CD25, CD69. 
Identifying CD4+ T cells biomarkers will be helpful to determine the difference in 
T cell subsets in each CD4+ T cells groups (stimulated/ non-stimulated). 
Infecting CD4+ T cells: 
Stimulated and non-stimulated CD4+ T cells will be infected with HIV WT. Cells 
will be stained with trypan blue stain to ensure cell viability. 
 One of the big concerns in this stage is that HIV WT could induce cell death. 
Therefore, using Drug resistant HIV variants is likely to be a good alternative strategy if 
HIV WT caused cell death. Another pitfall in our HIV latent cell paradigm is the spread 
of HIV in cell culture. Therefore, cell media will include antiretroviral drug to select for 
cells with HIV integration but not replication. 
Identifying Biomarkers for CD4+ T cells post infection: 
Same cell biomarkers in Bacchus et al. (2013) study will be identified which are: 
naive (CD45RA+CCR7+CD27+), central-memory (CD45RA-CCR7+CD27+) , 
transitional memory (CD45RA-CCR7-CD27+) , and effector memory cells (CD45RA-
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CCR7-CD27-) (Bacchus et al. 2013). in order to determine CD4+ T cells subsets after 
entering latency. Moreover, Ki67 and BrdU staining will be performed to check the 
proliferation stage of the cells. 
For further investigations, chromatin immunoprecipitation (ChIP) assay will be 
performed as described in Tyagi et al. (2007). ChIP assay will be performed in order to 
determine the levels of chromatin in resting primary CD4+ models. 
Long-term incubation:  
Cells will be incubated for long period using the H80 feeder cell line as 
previously described in the Tyagi and coworkers paradigm (Tyagi et al., 2010). 
Pitfall: HIV WT could infect H80 feeder cells. Thus, using H80 feeder cells 
supernatants may be a possible way to maintain HIV latent cells if our model cells 
survive, and to avoid an HIV cytopathic effect on H80 feeder cells if it occurs. 
AAV viral vector construction: 
 AAV viral vector will be constructed using the directed evolution method as 
previously described by Excoffon et. al (2009). Briefly, AAV2 and AAV5 cap genes will 
be amplified via PCR. DNA shuffling will be performed as previously described (Zaho  
et al., 1998; Stemmer, 1994). Next, the chimeric cap genes will be cloned in pSub2 for 
recombinant AAV (rAAV) construction (Maheshri et al., 2006). Error-prone PCR will be 
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done for subsequent evolution sequences (Maheshri et al., 2006). 
  The method for viral production will be as previously described by Excoffon and 
colleagues (Excoffon et al,. 2009). 
rAAV in vitro selection and characterization :  
To select the best AAV vector that is able to infect HIV latent cells, AAV will be 
diluted in EMEM and added to HIV latent cells. After 16 hours of incubation, 
unbound viruses will be washed off with PBS (Excoffon et al., 2009). Three days 
later, AAV vectors will be amplified by adding Ad5 as a helper virus, as previously 
described (Maheshri et al., 2006). After 3 days, AAV DNA will be recovered by PCR 
amplification and cloned into pSub2 to produce more rcAAV, and selected for pXX2 
NotI for rAAV production (Koerber  et al., 2008). 
To determine the relative efficiency of AAV transduction in HIV latent cells, the 
latter will be infected with rAAV vectors that carry cDNA encoding green fluorescent 
protein (GFP). The percentage of GFP cells will be quantified using flow cytometry 
48 hours post infection (Excoffon et al., 2009). Cells will be stained with Trypan blue 
to check viability.  
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